Advertisement

Table of Contents

What We're Reading

Obituary

Masters of Immunology

  • Masters of Immunology
    About the Masters
    Cancer Immunol Res April 1 2017 5 (4) 274-274; DOI:10.1158/2326-6066.CIR-17-0093

Meeting Report

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients
    Marlene Garcia-Neuer, Melina E. Marmarelis, Sushrut R. Jangi, Jason J. Luke, Nageatte Ibrahim, Meredith Davis, Janice Weinberg, Hilary Donahue, Nancy Bailey, F. Stephen Hodi, Elizabeth L. Buchbinder and Patrick A. Ott
    Cancer Immunol Res April 1 2017 5 (4) 286-291; DOI:10.1158/2326-6066.CIR-16-0302

    Checkpoint blockade is becoming more widespread, so the timely and accurate diagnosis of immune-related colitis is increasingly important. By comparing diagnoses with colonoscopy data, CT scans were a fast, accurate, and non invasive mode of diagnosing ipilimumab-induced immune-related colitis.

  • Cancer Immunology Miniatures
    Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers
    Andrew R. Green, Mohammed A. Aleskandarany, Reem Ali, Eleanor Grace Hodgson, Suha Atabani, Karen De Souza, Emad A. Rakha, Ian O. Ellis and Srinivasan Madhusudan
    Cancer Immunol Res April 1 2017 5 (4) 292-299; DOI:10.1158/2326-6066.CIR-16-0195

    This study provides clinical evidence that the interplay between DNA repair, CD8+ T cells, and expression of PD-L1 and PD-1 can promote aggressive tumor phenotypes. XRCC1-directed personalization of immune checkpoint inhibitor therapy may be feasible in breast cancer.

Research Articles

  • Research Articles
    Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases
    Jiemiao Hu, Chantale Bernatchez, Liangfang Zhang, Xueqing Xia, Eugenie S. Kleinerman, Mien-Chie Hung, Patrick Hwu and Shulin Li
    Cancer Immunol Res April 1 2017 5 (4) 300-311; DOI:10.1158/2326-6066.CIR-16-0234

    NKG2D-mediated immune surveillance is crucial for inhibiting tumor growth and metastases, but tumors often downregulate NKG2D ligands. A therapeutic strategy to restore tumor-specific expression of NKG2D ligands on solid tumors was developed that induced tumor regression and increased survival.

  • Research Articles
    Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    Guillermo De Velasco, Youjin Je, Dominick Bossé, Mark M. Awad, Patrick A. Ott, Raphael B. Moreira, Fabio Schutz, Joaquim Bellmunt, Guru P. Sonpavde, F. Stephen Hodi and Toni K. Choueiri
    Cancer Immunol Res April 1 2017 5 (4) 312-318; DOI:10.1158/2326-6066.CIR-16-0237

    A meta-analysis of immune checkpoint therapies showed a small but significant increase in the risk of developing key immune-related adverse events of any grade, as well as selected high-grade gastrointestinal and liver toxicities.

  • Research Articles
    Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells
    Haley L. Peters, Satyendra C. Tripathi, Celine Kerros, Hiroyuki Katayama, Haven R. Garber, Lisa S. St. John, Lorenzo Federico, Ismail M. Meraz, Jack A. Roth, Boris Sepesi, Mourad Majidi, Kathryn Ruisaard, Karen Clise-Dwyer, Jason Roszik, Don L. Gibbons, John V. Heymach, Stephen G. Swisher, Chantale Bernatchez, Gheath Alatrash, Samir Hanash and Jeffrey J. Molldrem
    Cancer Immunol Res April 1 2017 5 (4) 319-329; DOI:10.1158/2326-6066.CIR-16-0141

    Lung cancer cells exposed to granulocyte serine proteases increased the presentation of both endogenous peptides and the exogenous, protease-derived, HLA-A2-restricted PR1 peptide. Circulating CTLs specific for these peptides were identified in lung cancer patients.

  • Research Articles
    Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers
    Satish K. Noonepalle, Franklin Gu, Eun-Joon Lee, Jeong-Hyeon Choi, Qimei Han, Jaejik Kim, Maria Ouzounova, Austin Y. Shull, Lirong Pei, Pei-Yin Hsu, Ravindra Kolhe, Fang Shi, Jiseok Choi, Katie Chiou, Tim H.M. Huang, Hasan Korkaya, Libin Deng, Hong-Bo Xin, Shuang Huang, Muthusamy Thangaraju, Arun Sreekumar, Stefan Ambs, Shou-Ching Tang, David H. Munn and Huidong Shi
    Cancer Immunol Res April 1 2017 5 (4) 330-344; DOI:10.1158/2326-6066.CIR-16-0182

    Triple-negative breast cancers (TNBCs) are often infiltrated by T cells. These tumors counteracted T-cell activity through hypomethylated IDO1 promoters and increased IDO1 expression in response to IFNγ, providing a rationale for treatment of TNBC with IDO inhibitors.

Back to top

Jump to

Advertisement